Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient–Nhs Interactions and Hospital Resource use- Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1319
https://www.valueinhealthjournal.com/article/S1098-3015(15)03395-1/fulltext
Title :
Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient–Nhs Interactions and Hospital Resource use- Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03395-1&doi=10.1016/j.jval.2015.09.1319
First page :
A483
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
816